We are live on ! Find out more
PRME icon

Prime Medicine
PRME

192 hedge funds and large institutions have $343M invested in Prime Medicine in 2026 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 73 increasing their positions, 50 reducing their positions, and 25 closing their positions.

Upgrade to unlock
New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more call options, than puts

Call options by funds: $ | Put options by funds: $

more funds holding

Funds holding: →

2% more capital invested

Capital invested by funds: $337M → $343M (+$5.94M)

0.84% more ownership

Funds ownership: 53.75% → 54.59% (+0.84%)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
192
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$3.62M
Puts
$2.86M
Net Calls
Net Calls Change

Top Buyers

Rank Fund Capital Flow
1
+$7.51M
2
+$6.05M
3
+$4.76M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$3.8M
5
AIM
ARK Investment Management
Florida
+$3.34M

Top Sellers

Rank Fund Capital Flow
1
-$2.99M
2
-$2.02M
3
-$1.95M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.91M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
Alphabet Inc
California
$57.6M
BlackRock
2
BlackRock
New York
$29.6M
State Street
3
State Street
Massachusetts
$22.1M
AIM
4
ARK Investment Management
Florida
$21.7M
T. Rowe Price Investment Management
5
T. Rowe Price Investment Management
Maryland
$19.1M
VCM
6
Vanguard Capital Management
Pennsylvania
$15.6M
Balyasny Asset Management
7
Balyasny Asset Management
Illinois
$14.3M
CC
8
Casdin Capital
New York
$11M
WP
9
Woodline Partners
California
$10.5M
Sumitomo Mitsui Trust Group
10
Sumitomo Mitsui Trust Group
Japan
$10.2M
NAMA
11
Nikko Asset Management Americas
New York
$10.2M
UBS Group
12
UBS Group
Switzerland
$10.1M
Geode Capital Management
13
Geode Capital Management
Massachusetts
$9.55M
ACM
14
ADAR1 Capital Management
Texas
$6.87M
Fidelity Investments
15
Fidelity Investments
Massachusetts
$6.16M
RG
16
Redmile Group
California
$5.54M
Two Sigma Investments
17
Two Sigma Investments
New York
$5.47M
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$4.85M
FCM
19
Farallon Capital Management
California
$4.32M
Goldman Sachs
20
Goldman Sachs
New York
$3.38M
Charles Schwab
21
Charles Schwab
California
$3.19M
Northern Trust
22
Northern Trust
Illinois
$3.09M
VPM
23
Vanguard Portfolio Management
Pennsylvania
$3M
JP Morgan Chase
24
JP Morgan Chase
New York
$2.66M
GWM
25
Greenwich Wealth Management
Connecticut
$2.61M
1
2 3 4 5

PRME Hedge Fund Activity: Q1 2026 in Review

192 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q1 2026, worth a combined $343M — up 1.8% from $337M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new PRME positions and 25 closed out — a net gain of 14 holders — while 73 added to existing stakes and 50 trimmed.

The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $7.51M. The largest seller was Goldman Sachs, cutting an estimated $2.99M.

  • 192 institutional investors held Prime Medicine (PRME) as of Q1 2026, up from 183 in Q4 2025.
  • Funds reported $343M of Prime Medicine stock for Q1 2026, up 1.8% quarter-over-quarter.
  • 39 funds opened new Prime Medicine positions in Q1 2026 and 25 closed out, a net change of +14 holders.
  • The largest Prime Medicine buyer in Q1 2026 was ADAR1 Capital Management, an estimated $7.51M added.
  • The largest Prime Medicine seller in Q1 2026 was Goldman Sachs, an estimated $2.99M sold.

Based on aggregated 13F filings for Q1 2026.